US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry
US FDA’s recommendation against use of foreign-licensed reference products in clinical switching studies would result in procurement challenges and higher costs for biosimilar developers while also limiting where such studies could be conducted, some companies say.
You may also be interested in...
Sandoz, which used an EU-approved comparator in the switch study for its biosimilar Erelzi, might have to redo the trial in light of FDA’s draft guidance.
Company's application development seems to be outpacing FDA's policy development in next step along the 351(k) pathway.
Chief of new drugs office notes unintended consequence of safety legislation is thwarting development of ANDAs and biosimilars.